IP Library Granted Patent US 8,338,390
Granted Patent B2
US 8,338,390 · App. 12/767,931 · Granted Dec 25, 2012

Multifunctional and biologically active matrices from multicomponent polymeric solutions

Assignee: University of Delaware
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,338,390
App. No.
12/767,931
Granted
Dec 25, 2012
Kind
B2
Abstract

A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin.

Claims (12)

1. A functionalized polymer matrix for the controlled release in vitro or in vivo of a growth factor, the functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer comprising PEG, a low molecular weight heparin and at least one releasable growth factor, wherein the low molecular weight heparin is covalently attached to the compatibilizing polymer, and wherein the compatibilizing polymer comprises between about 0.35% wt/wt and about 0.95% wt/wt of the polymer matrix, wherein controlled release of the growth factor from the functionalized polymer matrix exhibits a linear controlled-release profile over at least seven days.

2. The functionalized polymer matrix of claim 1 , wherein the matrix polymer comprises polyurethane, collagen, PEO, PLGA, or combinations thereof.

3. The functionalized polymer matrix of claim 1 , wherein the at least one releasable growth factor is selected from the group consisting of PDGF, VEGF, and bFGF.

4. The functionalized polymer matrix of claim 3 , wherein the at least one releasable growth factor is PDGF.

5. The functionalized polymer matrix of claim 3 , wherein the at least one releasable growth factor is VEGF.

6. The functionalized polymer matrix of claim 3 , wherein the at least one releasable growth factor is bFGF.

7. The functionalized polymer matrix of claim 2 , wherein the matrix polymer comprises polyurethane.

8. The functionalized polymer matrix of claim 2 , wherein the matrix polymer comprises collagen.

9. The functionalized polymer matrix of claim 2 , wherein the matrix polymer comprises PEO.

10. The functionalized polymer matrix of claim 2 , wherein the matrix polymer comprises PLGA.

11. The functionalized polymer matrix of claim 1 , wherein 50% or less of the growth factor is released from the polymer matrix over seven days.

12. The functionalized polymer matrix of claim 1 , wherein the at least one growth factor is non-covalently bound to the low molecular weight heparin.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 4, 2021
From: UNIVERSITY OF DELAWARE
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 058024/0825 →
CONFIRMATORY LICENSE Recorded May 31, 2017
From: UNIVERSITY OF DELAWARE
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 042643/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2010
From: KIICK, KRISTI L.; YAMAGUCHI, NORI; RABOLT, JOHN; CASPER, CHERYL
To: UNIVERSITY OF DELAWARE
Reel/Frame 024941/0969 →
Continuity (3)
Continuation In Part 11395699 · Mar 31, 2006
Provisional Application 60666787 · Mar 31, 2005
Related Publication 20100297238A1 · Nov 25, 2010